60 DEGREES PHARMACEUTICALS, INC. (SXTP) 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
60 Degrees Pharmaceuticals, Inc. NASDAQ:SXTP Healthcare · Biotechnology
Mkt Cap $3.31M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 3
60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome
60 Degrees Pharmaceuticals signed a sponsored research agreement with the University of Southern Mississippi to evaluate castanospermine in nonclinical models of alpha-gal syndrome.
The company underwrites the research and retains an option to commercialize any resulting IP, with a possible botanical approval pathway ahead of any Rx development program.
There are no FDA-approved treatments for AGS, so the program addresses an unmet need, though it remains at a preclinical stage.
The release also reiterates the company's going-concern doubt and lack of manufacturing capacity, key risks alongside this early research.
• 4d ago AI analysis › Press Release ⚠ 4
60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients
All five completed patients (100%) in 60P's expanded access babesiosis study reported much or very much improved outcomes with negative conventional PCR tests, and 80% were negative on a highly sensitive post-treatment NAT assay.
Total enrollment is seven, with two patients still on treatment and the study open pending potential FDA discussions. The company plans to pursue accelerated approval using post-treatment NAT nonreactivity as a proposed surrogate endpoint.
A separate randomized, placebo-controlled hospitalized-babesiosis study (NCT06207370) is expected to unblind in January 2027, followed by a pre-sNDA meeting request with FDA. Tafenoquine is not FDA-approved for babesiosis; it is approved as ARAKODA for malaria prophylaxis.
• 5d ago AI analysis › Press Release ⚠ 4
60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA
60 Degrees Pharmaceuticals will conclude enrollment at 30 patients in its severe babesiosis study of tafenoquine after a DSMB interim analysis on October 1, 2026 recommended completing the originally planned 33-patient study with no safety signals identified.
Primary and secondary endpoint results are expected in January 2027, when the company will also request a pre-sNDA meeting with the FDA; management sees a possible accelerated approval pathway using NAT-based molecular clearance as a surrogate endpoint in treatment-refractory patients.
The first three patients in its expanded access study achieved molecular cure, with data from two more patients due in early November 2026; tafenoquine is not yet FDA-approved for babesiosis, and results remain binary risk for the micro-cap filer.
• 26d ago AI analysis › Press Release ⚠ 2
60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
RedChip Companies will air sponsored interviews with Exyn Technologies and 60 Degrees Pharmaceuticals on its Small Stocks, Big Money show, airing on Bloomberg TV October 3 and CNBC October 4.
Exyn CEO Ben Williams discussed the company's GPS-denied autonomy and 3D mapping software, touting more than 1,000 autonomous missions per month, an expanding defense pipeline including Exyn Defense and Green UAS certification, and API/OEM software-licensing strategies.
The release is paid investor-relations promotion: RedChip discloses it is compensated by both companies, and no new material financial or operational information is announced.
• 0mo ago AI analysis › Press Release ⚠ 2
60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar
60 Degrees Pharmaceuticals will disclose interim analysis results from its study of tafenoquine in hospitalized severe babesiosis patients on October 6, 2026.
The company will host a KOL investor webinar the same day featuring Yale's Dr. Peter Krause and Tufts' Dr. Edouard Vannier to discuss the unmet need and tafenoquine's mechanistic rationale.
No FDA-approved treatment for babesiosis exists, and tafenoquine is not approved for that indication; the data release is a near-term binary catalyst for the micro-cap.
The release's risk factors reiterate substantial doubt about the company's ability to continue as a going concern.
• 1mo ago AI analysis › Press Release ⚠ 2
60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference
60 Degrees Pharmaceuticals will participate in the H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026 in New York City.
A pre-recorded company presentation goes on demand September 11, 2026 at 7:00 a.m. ET through the conference portal, and management will hold one-on-one meetings with institutional investors during the event.
The release contains no new clinical, regulatory, or financial data — it is a routine investor-visibility announcement for the micro-cap, whose lead product ARAKODA is FDA-approved for malaria prevention and which has three active trials underway in babesiosis.
• 1mo ago AI analysis › Press Release ⚠ 2
60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results
60 Degrees Pharmaceuticals reported Q2 2026 net product revenue of $208,000, a 106% increase from the prior year's $101,000.
Despite the revenue growth, operating expenses rose to $2.33 million, resulting in a net loss of $2.40 million, or $0.90 per share.
The company's commercial product is ARAKODA for malaria prevention, and it currently has three clinical trials underway for babesiosis.
• 2mo ago AI analysis › Press Release ⚠ 2
60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules
60 Degrees Pharmaceuticals priced a private placement of 574,713 shares of common stock and accompanying warrants at $1.74 per share, aiming for gross proceeds of approximately $1.0 million.
H.C. Wainwright & Co. acted as the exclusive placement agent for the ATM offering, which includes Series A and Series B warrants exercisable at $1.49.
The company intends to use the net proceeds for working capital and general corporate purposes as it continues commercializing its lead product, ARAKODA, for malaria prevention.
• 3mo ago AI analysis › Press Release
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
60 Degrees Pharmaceuticals has enrolled the minimum 24 patients required to trigger an interim analysis in its clinical study of tafenoquine for severe babesiosis.
The company expects to disclose the outcome of this interim analysis no later than October 6, 2026, while enrollment continues in the double-blind, placebo-controlled trial.
Following the readout, the company plans to request a meeting with the FDA to discuss the regulatory pathway for a New Drug Application for tafenoquine in this indication.
• 3mo ago AI analysis › Press Release
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
60 Degrees Pharmaceuticals entered into an exclusive option agreement with the Florida State University Research Foundation to license IP for castanospermine targeting tick-borne diseases.
The agreement covers Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease, giving the company time to formulate a commercialization strategy.
Management indicated it will prioritize the prescription drug pathway for castanospermine while re-evaluating its strategy for the dietary supplement opportunity.
• 3mo ago AI analysis › Press Release ⚠ 2
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
60 Degrees Pharmaceuticals received a recommendation from the independent Data Safety Monitoring Board to continue the Phase 2 B-Free study of tafenoquine for chronic babesiosis. The review of safety data from the first six patients through Day 30 found no issues requiring study modification.
The study aims to enroll up to 100 patients to evaluate fatigue resolution over a 90-day ARAKODA regimen. Babesiosis is an orphan tick-borne disease with rising incidence and currently no FDA-approved treatments.
Tafenoquine is already approved for malaria prophylaxis in the U.S. and Australia under the ARAKODA and KODATEF brand names. The current study is funded by the U.S. Army Medical & Materiel Development Activity.
• 4mo ago AI analysis › Press Release ⚠ 2
60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement
60 Degrees Pharmaceuticals signed an exclusive patent license with Florida State University to extract castanospermine from Australian Chestnut seeds for non-prescription use.
The company will meet with the FDA on July 1, 2026, to discuss feedback on its New Dietary Ingredient Notification (NDIN) for Australian Chestnut Extract.
The release includes a cautionary note stating there is substantial doubt about the company's ability to continue as a going concern.
• 4mo ago AI analysis › Press Release ⚠ 2
60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
60 Degrees Pharmaceuticals enrolled the first patient in its clinical trial evaluating tafenoquine for the treatment of babesiosis, marking the start of the 2026 tick season recruitment.
The randomized, double-blind, placebo-controlled trial is being conducted at five sites in the northeastern U.S. and is tracking approximately one month ahead of schedule.
Minimum enrollment of 24 patients required for an interim analysis is expected as soon as early July 2026, with results to follow roughly 50 days later.
• 5mo ago AI analysis › Press Release ⚠ 3
60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
60 Degrees Pharmaceuticals reported Q1 2026 revenue of $162,000, a 1% decline year-over-year, with a net loss of $2.21 million ($1.28 per share).
Operating expenses rose to $2.17 million from $2.09 million in the prior year, while gross profit contracted to $76,000 from $90,000.
The company disclosed substantial doubt about its ability to continue as a going concern, citing reliance on future drug approvals and lack of manufacturing capacity.
• 5mo ago AI analysis › 
